DNA methylation as prognostic factors in non-muscle-invasive bladder cancer: a systematic review and meta-analysis
Oncology Reviews · 25.11.2025 · 19
DOI: 10.3389/or.2025.1679974 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Oncology Reviews, online erschienen am 25.11.2025. Verfasst von Vishwajeet Singh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, King George's Medical University, Lucknow, Uttar Pradesh, India. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Early prognostication in non-muscle-invasive bladder cancer (NMIBC) is essential for optimizing therapy and follow-up. Epigenetic mechanisms, particularly DNA methylation, have emerged as promising biomarkers for predicting disease outcome. Materials and Methods A systematic review and meta-analysis were conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to evaluate the prognostic significance of promoter DNA methylation in NMIBC. Comprehensive searches of PubMed, Web of Science, Embase, MEDLINE, and the Cochrane Library (January 2010–October 2022) identified eligible studies. The Newcastle–Ottawa scale was used for quality assessment, and pooled hazard ratios with 95% confidence intervals were calculated using random-effects models.
Results
Eleven studies with 3,065 NMIBC patients were analyzed. Promoter methylation was significantly associated with poor progression-free survival (pooled hazard ratios (HR) = 2.88; 95% CI = 2.03–4.09; p < 0.0001) and recurrence-free survival (pooled HR = 2.65; 95% CI = 1.93–3.63; p < 0.0001). Although overall survival showed pathway-specific variation (pooled HR = 0.96; 95% CI = 0.36–2.60; p = 0.94), methylation of adhesion and apoptosis-related genes exhibited the strongest associations. Subgroup analyses revealed a greater prognostic impact in Asian cohorts (p < 0.0001), suggesting regional differences in epigenetic susceptibility.
Conclusion
Promoter DNA methylation constitutes a robust prognostic biomarker for recurrence and progression in NMIBC, with stronger effects in Asian populations. Standardization of validated gene panels, assay thresholds, and cross-regional prospective validation will be essential for clinical translation. Integrating methylation-based classifiers into risk stratification models could improve individualized management and long-term outcomes in NMIBC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, King George's Medical University, Lucknow, Uttar Pradesh, India.
- Centre for Advance Research, King George's Medical University, Lucknow, Uttar Pradesh, India.
- Central Research Facility, Post Graduate Institute of Child Health, Noida, Uttar Pradesh, India.
- Department of Thoracic Surgery, King George's Medical University, Lucknow, India.
- Department of Biochemistry, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
Zitieren
APA
Singh, V., Singh, M. K., Kumar, A., Shrivastava, A., Sahu, D. K., Jain, M., & Pandey, A. K. (2025). DNA methylation as prognostic factors in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. Oncology Reviews, 19. https://doi.org/10.3389/or.2025.1679974
Vancouver
Singh V, Singh MK, Kumar A, Shrivastava A, Sahu DK, Jain M, et al. DNA methylation as prognostic factors in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. Oncology Reviews. 2025;19. doi:10.3389/or.2025.1679974
BibTeX
@article{Singh2025,
author = {Singh, Vishwajeet and Singh, Mukul Kumar and Kumar, Anil and Shrivastava, Ashutosh and Sahu, Dinesh Kumar and Jain, Mayank and Pandey, Anuj Kumar},
title = {DNA methylation as prognostic factors in non-muscle-invasive bladder cancer: a systematic review and meta-analysis},
journal = {Oncology Reviews},
year = {2025},
volume = {19},
doi = {10.3389/or.2025.1679974}
}
EUVIMED